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Latest Developments in Metalloenzyme Design and Repurposing 
Tillmann Heinisch[a] and Thomas R. Ward*[a] 
Abstract: In the past decade, artificial metalloenzymes have 
emerged has attractive alternatives to more traditional homogeneous 
catalysts and enzymes. This microreview presents a selection of 
recent achievements in the design of such hybrid catalysts. These 
include artificial Zn-hydrolases and metathesases, the heme-protein 
repurposing for C-H, N-H and S-H insertion reactions, novel light-
driven redox hybrid catalysts, novel scaffold proteins and 
metallocofactor anchoring techniques and metalloenzyme models.  
1. Introduction
The ever increasing wealth of structural and functional data 
accumulated for proteins encourages to probe and widen our 
knowledge of enzymes experimentally by creating artificial 
(metallo)enzymes (AME hereafter) or by exploring latent 
activities of natural metalloenzymes by redesign.1,2 Designing 
proteins and hybrids for novel functions is not only a valuable 
exercise for academic research but holds promise for  
Thomas R. Ward obtained his PhD in 
chemistry at the ETHZ under the guidance of 
Profs. L-M Venanzi and D. Seebach. After 
postdocs with Roald Hoffmann and Carlo 
Floriani, he initiated his carreer in 
bioinorganic chemistry (University of Berne) 
and bio-inspired catalysis (University of 
Neuchatel). In 2008, he moved to the 
University of Basel and runs a group focusing 
on the exploitation of artificial 
metalloenzymes in vivo.  
Tillmann Heinisch received his PhD in 
Chemistry and Protein Crystallography at the 
University of Basel under Prof. T. R. Ward 
and T. Schirmer. After joining the group of 
Prof. Frances Arnold at Caltech for 
postdoctoral research he returned to Basel 
for a second postdoc. His research interest is 
the structure-based engineering of artificial 
metalloenzymes.  
applications in medicine, synthesis and biotechnology. This 
microreview aims to provide insight into the latest examples of 
AME design and metalloenzyme repurposing including zinc 
hydrolases, novel C-H, N-H, S-H insertion reactions, light-driven 
redox reactions, novel protein scaffolds for metalloenzyme 
engineering and metallocofactor anchoring techniques, the in 
vivo application of AMEs and metalloenzyme models. 
2. Zn-Hydrolases
Zn-hydrolases have attracted wide attention in the protein 
design community. This might relate to the abundance and 
fundamental functions of zinc-hydrolases in nature, the relative 
simplicity of the catalyzed hydrolysis reactions, the availability of 
structural and functional data for zinc hydrolases and the relative 
ease with which models of zinc hydrolases can be generated 
and evaluated.3,4 
In many metalloenzymes, catalytic metals act as Lewis acids 
rather than redox-active cofactors (e.g. kinases, class 1 terpene 
synthases, peptidases). In zinc hydrolases, the metal adopts 
either a 4-coordinate tetrahedral or a 5-coordinate distorted-
trigonal bipyramidal geometry and is often coordinated by lone 
pairs of nitrogen or oxygen of His, Glu or Asp side chains. 
Typically water occupies initially a remaining coordination site at 
the metal which results in a dramatic reduction of its pKa value 
by 8 to 12 units in combination with H-bonding interactions of 
surrounding amino acids. The acidified water (or the 
corresponding hydroxo) attacks an electrophilic function of the 
substrate such as a carbonyl or phosphonate group leading to 
the formation of a negatively charged tetrahedral or trigonal-
bipyramidal intermediate or transition state, respectively. The 
intermediate is frequently stabilized by a positively charged or 
polarized “oxyanion hole” provided by proximal protein residues. 
The scissile C-O, C-N or P-O bond is subsequently cleaved and 
the two products are released. Enhanced nucleophilicity of 
coordinated water through Lewis acid coordination can be 
operational in ester, amide and phosphoester hydrolysis but also 
in addition reactions such as the hydration of carbon dioxide or 
enones. 
In Nature, ZnII ions are coordinated to side chains of amino acids 
that are part of distinct secondary structural motifs such as β-
sheets or α-helices. In a de novo approach, Pecoraro and 
coworkers computationally designed a peptide that assembles 
into a 3-α-helical bundle and is stabilized upon ZnII ion 
coordination through a (His)3 motif. Zinc is located at one end of 
the resulting bundle and  each His is located on an individual α-
helix (Figure 1).5 The 3-helix bundle is stabilized on the opposite 
end by a HgII ion coordinated to a (Cys)3 motif. The crystal
structure of the resulting hybrid catalyst showed that the catalytic 
ZnII-bound water in the center of the bundle was virtually 
superimposable with the corresponding (His)3(H2O)Zn
II site in
human carbonic anhydrase II (hCAII hereafter). In CO2 hydration, 
the catalyst has a very high catalytic constant (kcat) of 1800 s
-1,
which is only 100-fold smaller than that of natural hCAII, and a 
Michaelis constant (KM) 10-fold lower than that of hCAII.    
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Figure 1. Artificial Zn-hydrolases. 
 
Kuhlman and coworkers engineered the interface of a 
computationally designed homodimer of a helix-turn-helix protein 
to bind zinc to an engineered (His)3 motif.
6 The hybrid catalyst 
was structurally characterized and displays p-nitrophenol 
acetate (pNPA hereafter) hydrolase activity. A 50-fold decreased 
KM for this reaction vs. hCAII indicated strong substrate binding 
but a kcat of 0.3 s
-1 resulted in a limited catalytic efficiency.  
 
An α-helical fold was the template of an artificial Zn-hydrolase 
engineered by Tezcan and coworkers.7 In a related approach to 
Kuhlman et al., they modified surface residues that triggered a 
monomeric cytochrome P450 cb562 to form a D2 symmetrical 
homotetramer stabilized by disulfide bridges as well as 
hydrophobic and metal coordinating interactions. Additional 
positioning of a (His)2Glu motif into the  surface exposed fraction 
of a monomer-monomer interface allowed binding of a second 
ZnII ion as a  catalytic center upon decreasing the bulk at 
positions K104A and E57G. Substrates pNPE and ampicillin 
were hydrolyzed by the designer enzyme with catalytic 
efficiencies of 32 and 5.8 s-1M-1, respectively. The in vivo 
compatibility of this artificial ampicillinase was demonstrated by 
periplasmic expression in E. coli, which enabled cell growth on 
ampicillin-supplemented agar.  
 
Although α-helical proteins predominate the field of artificial Zn-
hydrolases, Korendyrovych and coworkers could demonstrate 
that a (His)3Zn
II catalytic site can be engineered into the strand-
strand interface of a β-sheet which is reminiscent of the hCAII 
active site. The authors exploited the self-assembly of short 
peptides into amyloid fibrils to design a moderately active Zn-
hydrolase.8  
 
Natural zinc sites can also be repurposed for novel function. 
Baker, Tawfik and coworkers used the RosettaDesign algorithm 
to screen an in silico designed theozyme against the protein  
data bank (PDB hereafter) for Zn-proteins with potential activity 
in hydrolysis of organophosphonate nerve agents. The authors 
identified mouse adenosine deaminase to display hydrolysis 
activity for a colorimetric organophosphonate substrate 
surrogate upon introduction of  the residues suggested by 
RosettaDesign (Figure 1, substrate 4).9 After three rounds of 
directed evolution the catalytic efficiency of the initial 
computational design was 2500-fold improved, almost 
exclusively by an increase in kcat.  
 
 
3. New Reactions 
AME design has the potential to expand Nature´s enzymatic 
reaction repertoire by introducing abiotic catalytic entities 
developed that have no equivalent among natural enzymes. We 
summarize below the latest additions to the portfolio of AME-
catalyzed reactions.   
3.1. Metathesases 
Olefin ring-closing metathesis (RCM) is a widely applicable and 
selective reaction for the intramolecular formation of internal 
C=C double bonds from olefins (Figure 2). One of the most 
widely used catalysts is the Grubbs-Hoyveda 2nd generation 
ruthenium complex. Importantly, it is water compatible, albeit 
with reduced productivity.10,11 Several groups set out to 
investigate if the catalyst can be anchored to a protein and if the 
protein environment can exert a positive effect on its activity 
(rate) and productivity (total turnover number = TON).  
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Figure 2. Artificial Metathesases 
 
 
In one of the first reports, Ward and coworkers linked the 
complex to D-biotin via its NHC backbone and incorporated the 
resulting construct into avidin which has a very high affinity for 
D-biotin (Kd = 10
-14 M, Figure 2).12 Under acidic conditions and in 
the presence of high concentrations of MgCl2 (0.5 M) – 
beneficial presumably thanks to reduced catalyst coordination to 
surface residues – the hydrophobic substrate N-tosyl diallyl 
amine 5 (TDA hereafter) was transformed into N-tosyl-3-
pyrroline by ring-closing metathesis with a total turnover number  
of up to 20, comparable to the catalyst in the absence of the 
host protein. 
 
Hilvert and coworkers chose the small heat shock protein 
MjHSP to anchor the ruthenium catalyst covalently via a 
cysteine (G41C) residue introduced in a strategic position at the 
rim of the β-barrel protein.13 With TDA as substrate, the hybrid 
catalyst performed best under acidic conditions (pH 2.0) but with 
a slightly reduced TON (25) relative to the free catalyst (33). 
 
Hirota and coworkers applied a “trojan horse” covalent coupling 
strategy to incorporate the ruthenium catalyst into α-
chymotrypsin.14 For this purpose they attached the catalyst via a 
glutamate linker to a hydrophobic peptide substrate motif of the 
serine protease. The C-terminal end of the peptide was modified 
to a chloroacetate group which enabled covalent-bond formation 
between the cofactor and the Ser side chain of the catalytic triad 
in the protein active site. The resulting hybrid catalyst yielded up 
to 4 turnover for substrate TDA under neutral conditions, in the 
presence of KCl and at only 25 µM catalyst concentration. 
However, the free cofactor was more productive (TON = 12) 
under identical conditions.  
 
The Grubbs-Hoyveda 2nd generation catalyst can also be used 
for ring-opening olefin polymerization (ROMP). Okuda and 
coworkers tethered the catalyst to the β-barrel pore protein FhuA 
via an engineered Cys at the entry of the pore.15,16 Successful 
attachement was confirmed by MS and a TON of up to 955 was 
reached with substrate 7-oxanorbornene 6, about the same as 
with the Ru catalyst alone. The cis/trans selectivity was 
moderately affected by the protein (70:30 for the free catalyst vs 
60:40 for the hybrid catalyst). 
 
These examples demonstrate the tolerance of the Grubbs-
Hoyveda catalyst for protein conjugation. However, no protein 
dependent rate acceleration was yet observed in any of the 
studies. It remains to be investigated whether initial metathesase 
designs can be optimized through protein engineering 
techniques.  
 
 
3.2. C-H, N-H, S-H Insertion Reactions 
 
While the AME designs in the last chapter were based on 
covalent or supramolecular anchoring of an artificial 
metallocofactor within a rigid protein scaffold, the examples in 
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the following exploit the principle of enzyme repurposing to 
create novel enzymatic function.  
 
Proteins containing an iron porphyrin prosthetic group are very 
diverse and highly abundant in Nature. They serve several 
functions such as electron transport, small molecule binding and 
redox catalysis.17 Cytochromes P450s catalyze among other 
transformations the hydroxylation of aliphatic or aromatic C–H 
bonds. In these reactions, an intermediate ferryl moiety (Fe(IV)-
oxo, compound 1) which is generated from O2 and two electrons, 
is the oxidizing species which cleaves a substrate C–H bond by 
hydrogen atom abstraction. The groups of Arnold and Fasan 
have now demonstrated that formal Fe(IV)-carbenoid and 
Fe(IV)-nitrenoid compounds, which are isoelectronic to Fe(IV)-
oxo, are generated in various heme proteins and insert into C–H, 
N–H and S–H bonds. These C-C, C-N and C-S bond-forming 
reactions catalyzed by designed metalloenzymes are valuable 
since they proceed in water, at room temperature and are very 
stereoselective which is difficult to achieve with chemical 
catalysts.18–20 The following carbene and nitrene transfer 
reactions have been described to be catalyzed by the iron 
porphyrin proteins: i) carbene transfer: cyclopropanation,21–26 
amination,27,28 sulfidation,29 ii) nitrene transfer: sulfamination,30–33 
sulfimination,34 oxazolidinone formation.35 
 
Cylcopropanation, amination, sulfidation: 
 
To form the Fe(IV)-carbenoid intermediate, low spin ferric heme 
must be reduced into low spin ferrous heme prior to reaction 
with a diazo compound, e.g. ethyl diazoacetate (EDA hereafter). 
The Fe(IV)-carbenoid can undergo reaction with various 
aromatic nucleophiles such as i) olefins (e.g. styrene) to form 
cyclopropanes,21–26  ii) prim. or sec. anilines to form sec. or tert. 
anilines27,28 or iii) thiols to form sulfides.29   
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Figure 3. Heme enzymes for C-H, N-H, S-R insertion reactions.  
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In cyclopropanation, diastereoselectivity and enantioselectivity is 
induced by the protein environment e.g. in the reaction between 
styrene and EDA. For the free hemin the (rac)-trans-
cyclopropane is formed preferentially (86:14). With hybrid 
catalyst P450BM3 mutant P411BM3-CIS (which contains thirteen 
mutations including an axial Ser ligand) the cis-cyclopropane is 
produced (10:90) in high enantiopurity (eecis 99% (1R,2S), 
Figure 3a).26  
 
Besides P450BM3 i) other cytochrome P450s such as CYP119, 
CYP153 or TxtE,22 ii) heme protein myoglobin21 and even iii) 
non-heme proteins in the presence of hemin catalyze the 
reaction.22 Every protein displays a different reactivity and 
selectivity (Figure 3a).  
 
Mutation of the axial Cys to Ser shifts the Soret band of the 
protein ferrous-CO complex from 450 to 411 nm (hence the 
name P411 of the constructs). It also decreases the redox 
potential of FeIII/II from E°´= -420 mV to E°´= -293 mV so that the 
reduction of the ferric low spin resting state is possible either 
with sodium dithionide (E°´=-660 mV) and with NADPH (E°´=-
320 mV, all potentials vs. SHE).26 This allows the reaction to 
proceed in cellulo. Whole cell E. coli biotransformation with 
P411BM3-CIS yielded > 60’000 TON .  
 
Decreasing the electron density at the Fe(IV)-carbenoid 
facilitates the nucleophilic attack of styrene. This is achieved by 
replacement of the axial thiolate ligand steming from Cys or the 
alkoxide ligand stemming from Ser for less electron-rich amino 
acid side chains such as the phenolate of Tyr, the imidazole of 
His, or by removing the axial ligand altogether as realized in an 
Ala mutant. Indeed, P450BM3-axHis performed best in whole cell 
cyclopropanation of styrene and EDA.25 P450BM3-axMet yielded 
second most product followed by Tyr>Ala>Ser>Cys which was 
essentially inactive. Myoglobin which bears His in the axial 
position, is a very good cyclopropantation catalyst yielding a 
TON of more than 45’000.21  
 
While styrene is a good substrate, electron-deficient N,N-diethyl-
2-phenylacrylamide was expected to be a poor nucleophile for 
Fe(IV)-carbenoid attack. The product of this reaction is a 
precursor of levomilnacipran, a potential drug to treat depression. 
Of the axial mutants initially tested, P450BM3T268A-axHis was 
the best catalyst for this substrate with a TON of 7100 and 94 % 
cis-selectivity but only moderate enantioselectivity (42 % ee).25 
To improve the ee, active site residues were targeted for 
saturation mutagenesis. Mutant P450BM3T268A-axHis-L437W-
V78M-L181V was found to produce levomilnacipran precursor 
with 98 % cis-selectivity, 92 % ee and at a very high rate of more 
than 1000 turnover min-1 (~8000 TON), Figure 3b. Working 
under aerobic conditions is not detrimental to the yield with this 
mutant anymore, which might be related to the high reaction rate.  
 
Besides olefins, nitrogen and sulfur nucleophiles have been 
successfully employed for the reaction with the Fe(IV)-carbenoid. 
While cytochrome P450BM3-CIS yields a TON of 433 in the 
reaction of EDA with aniline, the myoglobin variant H64V-V68A 
leads to a TON of 6150.27,28 Recently, Fasan and coworkers 
demonstrated a carbene insertion into S-H bonds with 
myoglobin.29 Thioaniline yields a TON of 2550 with EDA. Ethyl 
2-diazopropionate reacts with thioanillin to yield after 
rearrangement ethyl 2-thioanillinpropionate. 
 
Sulfonamides, sulfimides and oxazolindinones: 
 
Besides reactions proceeding through presumed Fe(IV)-
carbenoids, intermediate Fe(IV)-nitrenoids are likely formed by 
reaction of ferrous low spin iron porphyrin protein with 
sulfonylazides or carbonazidates. The intermediates can 
undergo intramolecular C-H insertion to form cyclic 
benzosultams or can form sulfimides in an intermolecular 
reaction with sulfide nucleophiles (Figure 3e-h).  
 
The cyclization of 2,4,6-triethyl-benzene-1-sulfonylazide 
proceeds best using P411BM3-CIS-T438S which includes 
fourteen mutations including a Ser as an axial heme ligand 
instead of Cys.30 This mutant yields the corresponding 
benzosultam with a TON of 383 and 73 % ee. The reaction can 
be carried out in cellulo to yield a TON of up to 430 and an 
improved ee of 87 % (Figure 3e).  
 
                                                                                                        
 
 
Besides P450BM3 other heme proteins such as horse radish 
peroxidase and myoglobin have been reported by Fasan and 
coworkers to catalyze intramolecular C-H sulfamination with 
TONs of 311 and 181, respectively (Figure 3f).31  
 
As an alternative to sulfonylazides, carbonazidates have been 
employed yielding oxazolidinones in the presence of cytochrome 
CYP102A1 with a TON of 20 (Figure 3i). 35  
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Figure 4. Proposed catalytic mechanism of non-heme iron halogenase SyrB2 
with natural substrate chloride and surrogates N3
-
 and NO2
-
. 
 
The intramolecular sulfamination reaction is believed to proceed 
through abstraction of a hydrogen by the nitrene intermediate 
and subsequent radical rebound reaction.35 If the protein has 
only little control over substrate positioning, hydrogen 
abstraction should occur from the weaker benzylic (bond 
dissociation energy, BDE, 85 kcal/mol) rather than the stronger 
homobenzylic (BDE 98 kcal/mol) alkyl C-H bond by the nitrene. 
In principle, reshaping the enzyme active site could trigger 
hydrogen abstraction from the stronger homobenzylic C-H group. 
This was tested with substrate 2-propyl-5-ethylcarbonyl-
benzene-1-sulfonylazide.32 It was found through saturation 
mutagenesis of various active site residues that variant P411BM3-
CIS-I263F-T438S has strong β-selectivity (95:5) whereas 
P411BM3-CIS-T268A-F87A has strong α-selectivity (5:95). The 
reactions proceed with excellent enantioselectivity (Figure 3g). 
 
Intermolecular C-H sulfamination has not been achieved yet. 
However, it was demonstrated that sulfide nucleophiles react 
with nitrenes in an intermolecular fashion. 4-methylbenzene 
sulfonylazide in reaction with methylphenylsulfide yields the 
corresponding sulfimides with up to 300 TON and 64 % ee 
(Figure 3h).34 
 
Alkane nitration: 
 
Halogenation of C-H bonds is carried out in Nature mostly by 
oxidative enzymes that belong to one of the three classes: i) 
heme-dependent haloperoxidases, ii) vanadium-dependent 
haloperoxidases and iii) non-heme iron -ketogluterate-
dependent haloperoxidases.36 In the resting state of non-heme 
iron haloperoxidases ferrous iron is coordinated by two His, two 
H2O and -ketogluterate (Figure 4). In the putative catalytic 
cycle the equatorial H2O is replaced by a halide ion. Upon 
substrate binding, the axial H2O is replaced by O2. The Fe(III)-
dioxy compound rearranges in an oxidative decarboxylation to 
form Fe(IV)-oxo. This species can abstract a hydrogen from the 
substrate C-H to form Fe(III)-OH. The alkyl radical undergoes a 
radical rebound reaction with the halide ligand to form the alkyl 
halide product and Fe(II). Succinic acid is replaced by another 
molecule -ketogluterate to close the catalytic cycle.37,38  
 
It has now been shown by Bollinger 
and coworkers that the halide ligand 
can be replaced by nitride or azide 
ions which equally to halides can 
undergo a radical rebound reaction 
with the intermediate substrate radical 
in non-heme iron halogenase SyrB2.39 
Even though only a single turnover 
could be performed with this enzyme, 
improvement of the catalyst can be 
imagined by means of protein 
engineering.   
 
 
3.3. Light-Driven Redox Reactions  
 
With respect to renewable energy sources it is highly desirable 
to apply cheap reductants in concert with photocatalysts for the 
generation of high-energy (e.g. H2) and added-value 
compounds.40 In Nature, diiron dithiolate hydrogenases catalyze 
H2 evolution formally from two electrons and two protons with a 
very high rate of >100’000 min-1.41 However, it is difficult to 
prepare this multidomain enzyme in large quantities for cheap H2 
production. Various groups have attempted to develop smaller 
derivatives of natural hydrogenases based on the immobilization 
of synthetic cofactors inside scaffold proteins or by modification 
of natural hydrogenase.42–45  
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Figure 5: Photocatalytic artificial metalloenzymes. 
 
 
 
Nitrogenase catalyzes the six electron reduction of N2 into two 
equivalents of NH3. In the reaction, one equivalent of H2 is 
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formed as a byproduct. The enzyme complex consists of two 
components, the iron protein (FeP) and the molybdenum-iron 
protein (MoFeP). The MoFeP contains two metal clusters with 
FeMoco being the reaction center. Electrons are shuttled from 
FeP into MoFeP under consumption of 16 ATP molecules per 
molecule N2. To uncouple the enzyme from the costly ATP 
consumption, Tezcan and coworkers developed a hybrid 
photocatalyst that contains the MoFeP as the redox catalyst and, 
instead of the FeP, includes a covalently anchored 
[Ru(bpy)2(PhenA)]
2+ photosensitizer/mediator (PS/M hereafter) 
pair.46,47 Under irradiation with visible light and with sodium 
dithionide as the sacrificial reductant, this hybrid enzyme 
catalyzes H2 evolution, acetylene reduction and six-electron 
cyanide reduction (to methane) with multiple turnover (Figure 
5b). A similar approach was followed by Cheruzel and 
coworkers in their attempt to uncouple the heme domain of 
hydroxylating enzyme cytochrome P450BM3 from its reductase 
domain and thereby replace costly NADPH by sodium 
diethyldithiocarbamate as an electron source.48 The catalytic 
heme domain was covalently functionalized with PS/M 
[Ru((OMe)2bpy)2(PhenA)]
2+. This hybrid system catalyzed 
hydroxylation of lauric acid with a TON of more than 900 (Figure 
5a). Inspired by natural hydrogenases, Hayashi and coworkers 
developed a hybrid system consisting of a scaffold peptide 
comprising the 18 N-terminal amino acids of cytochrome c556, 
functionalized with a [Fe2(CO)6] cluster bound to two Cys 
thiolates as the redox catalyst and His imidazole-tethered 
[Ru(bpy)(typ)]2+ as PS/M.49 This minimalistic hydrogenase model  
evolved H2 with a TON of up to 9 (Figure 5c). In another design, 
the same group tethered the diirondithiolate catalyst [(μ-
S)2Fe2(CO)6] via a maleimide anchor to a Cys side chain of β-
barrel protein nitrobindin. Even though no protein rate 
acceleration for H2 evolution was observed, the diirondithiolate 
moiety is functional within this protein scaffold (TON = 130), 
Figure 5f.50 The H-cluster, the reaction center of hydrogenase 
HYDA consist of a simple [2Fe-2S] cluster linked via a Cys 
bridge to the [2Fe] cluster that contains the diirondithiolate 
motive. In nature, maturation of the [2Fe]-cluster requires three 
additional enzymes,  
 
HYDE, HYDF, HYDG. This sophisticated assembly renders the 
efficient heterologous production of hydrogenase difficult. 
However, Happe and coworkers have shown that a close 
synthetic mimic of the [2Fe] cluster can be added to apo-HYDA, 
which only contains the [2Fe-2S]-cluster, to obtain a 
hydrogenase (up to 100’000 turnover min-1). The construct 
shows virtually no loss of activity vs. the natural enzyme in the 
light-driven protein reduction using photosystem I as the PS/M 
couple and ascorbate as a sacrificial reductant.51 The apo-
enzyme could be readily expressed in E. coli, Figure 5d. 
 
 As an alternative to diirondithiolate redox catalysts, cobaloximes 
have been investigated for H2 evolution. Artero and coworkers 
functionalized apo-sperm whale myoglobin with two cobaloxime 
complexes.52 The researchers assumed that coordination of 
cobaloxime to axial His93 generated the catalytically active 
species. In the presence of [Ru(bpy)3]
2+ and ascorbate a TON of 
3 for the production of hydrogen was observed. The free 
cobaloxime, however, had slightly better reactivity, Figure 5e.  
Nickel complex [Ni(P2PhN2Ph)2]
2+ is another excellent H2 
evolution catalyst. Utschig and coworkers have introduced this 
catalyst into a hybrid system with photosystem I as host protein. 
In the presence of ascorbate as sacrificial reductant, it evolves 
H2 with a TON of 3000, Figure 5g.
53   
 
4. New Scaffolds 
In the last decade a growing number of protein scaffolds have 
been used to design AMEs. Here we present the latest reports in 
respect to scaffold diversity.  
Peptide dendrimers resemble proteins in their polymeric Nature 
but are generally structurally less well-defined and hence more 
flexible. This additional flexibility can be considered as an 
additional design challenge for hybrid catalysts. Reymond and 
coworkers presented a peptide dendrimer with a [Fe(bpy)3]
2+ 
core that displayed peroxidase activity. The amino acid 
decoration surrounding the iron core led to a 10-fold rate 
acceleration compared to  [Fe(bpy)3]
2+.54 
Bacterial pore FhuA is a large beta-barrel protein. It has been 
employed by Hayashi and Schwaneberg to create covalent 
AMEs for Ru-catalyzed metathesis15 and Rh-catalyzed 
phenylacetylene polymerization.55 Although similarly active, 
tethering of the CpRh(COD) catalyst to the protein altered the 
cis/trans selectivity of the polymerization towards 47:53 vs. 93:7 
for the free catalyst.  
Metallothioneins are Cys-rich proteins responsible for the 
storage of mono- and divalent metal ions such as FeII, CoII, NiII 
and others. The 32-amino acid metallothionein -domain known 
to bind a 4-metal ion cluster by interactions with 11 Cys residues, 
was prepared by solid-phase peptide synthesis and incubated 
with FeCl2 by Hayashi and coworkers.
56 In single turnover 
experiments this reducing agent was able to effect single 
electron reduction of Mb and the four-electron reduction of diazo 
compound methyl red into two equivalents of aniline. Nitrobindin 
is a heme-binding bacterial β-barrel protein which can 
accommodate synthetic catalysts linked covalently via cysteine 
residues. Hayashi and coworkers used this strategy to 
incorporate CpRh(COD)+ and investigated phenylacetylene 
polymerization. With a crystal structure of the catalyst at hand, 
the authors selected residues in proximity to the metal for 
mutagenesis studies. The cis:trans ratio of the polymeric product 
is significantly influenced by the protein environment. One 
mutant showed 82% enrichment of the trans-product whereas 
the free catalyst was highly cis-selective (93:7).57 Lewis and 
coworkers used the same scaffold to incorporate a [Mn(tpy)]2+ 
complex and tested benzylic oxidation. In the presence of 
peroxyacetic acid, benzylic methylene groups were oxidized into 
carbonyls and styrene into phenyl epoxide.58 Ueno and 
coworkers applied a -helical protein nanotube equipped with 
Cys residues to covalently attach a bipyridine ligand to bind the 
water compatible Lewis acid Sc3+. This hybrid catalyst was 
employed in the enantioselective ring opening of cis-stilbene 
epoxide  with aniline as a nucleophile.59 Ricoux and coworkers 
used xylanase as a scaffold to bind MnIII-meso-tetrakis(p-
carboxyphenyl)-porphyrin and MnIII-salen with micromolar affinity. 
These catalysts were successfully applied in the oxidation of 
styrene derivatives with oxone as the stoichiometric oxidant.60  
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Neocarcinostatin has been shown to bind a testosterone-
conjugated iron porphyrin complex. The hybrid complex was 
used by Ricoux and coworkers to oxidize sulfides into sulfoxides 
using H2O2. However, the protein decelerated the reaction and 
only 13 % ee was observed.61 
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Figure 6. Novel anchoring strategies for synthetic metallocofactors within 
proteins (a) and in vivo applications of transition metal catalysts (b). 
 
 
RNase A contains an N-terminal α-helix (S-peptide) which can 
be cleaved off yielding a stable residual protein called S-protein. 
Upon mixing of the S-protein with the S-peptide, full nuclease 
MICROREVIEW          
 
 
 
 
 
activity is restored. Inspired by a study by Imperiali and 
coworkers62, Sträter and coworkers, equipped the S-peptide with 
His residues in strategic positions to enable selective binding of 
the fragment Cp*RhCl and Cp*IrCl. The hybrid catalyst showed 
low enantiomeric induction and protein rate acceleration in the 
transfer hydrogenation of cyclic imines.63 Human carbonic 
anhydrase II binds aryl sulfonamide inhibitors with nanomolar 
affinity. In a supramolecular strategy, Ward and coworkers 
tethered complex  [Cp*IrCl(pico)] to benzylsulfonamide which 
results in a catalyst that binds to hCAII with low nanomolar 
affinity. In imine transfer hydrogenation, the hybrid catalyst 
showed up to 70% ee for the S-amine product which was 
produced with a TON of 9 at 4 °C (40 TON at 40 °C).64 
A novel protein dimer, LmrR, was used as scaffold by Roelfes 
and coworkers to covalently attach a phenantroline ligand. When 
incubated with CuII, an active Diels-Alderase was obtained that 
could be optimized by genetic modification of the active site to 
produce up to 97% ee and a TON of 33 in the reaction of 
cyclopentadiene with α,β-unsaturated acylpyridine.65 The protein 
scaffold accelerated the reaction almost 5-fold. The same 
catalyst displayed hydratase activity for the same enone 
substrate employed as a dienophile in the Diels-Alder reaction 
with up to 84 % ee.66  
 
 
5. New Anchoring Methods 
Finding the right anchoring strategy is crucial to building an 
efficient AME from a protein scaffold and a metal catalyst. 
Traditionally, three anchoring methods have been used: 
covalent, supramolecular and dative anchoring. Covalent 
anchoring relies on the incorporation of reactive Cys in a 
strategic position within the protein cavity. However, limited 
labeling selectivity often requires Cys-to-Ala mutation to prevent 
undesired modifications on native Cys residues. To overcome 
this problem, Lewis and coworkers have exploited an orthogonal, 
highly specific strategy for catalyst incorporation.67 Using the 
amber stop codon, they genetically introduced the unnatural 
amino acid (UAA hereafter) p-azido-Phe in a cavity within the 
thermostable protein tHisF and coupled it to a cyclooctyne-
functionalized dirhodium catalyst via a strain-promoted click 
reaction. The hybrid catalyst was active in the cyclopropanation 
of styrene with EDA but no protein rate acceleration was 
observed, Figure 6a. 
Roelfes and coworkers followed a strategy described earlier by 
Schultz.68 Using the amber stop codon strategy they 
incorporated the bipyridinyl-Ala UAA into the protein LmrR 
(Figure 6a).69 Upon addition of CuII, the hybrid catalyst was 
active in the asymmetric Friedel-Crafts alkylation of indole with 
an enone electrophile. Genetic optimization of active site 
residues yielded a mutant that produced the product with 83 % 
ee and a TON of 11.  
6. In vivo Application of Transition Metal 
Catalysts 
 
 
 
 With respect to future applications of AMEs in artificial 
metabolic pathways it is essential to identify methods to ensure 
the catalytic activity of transition metals in vivo. Many cellular 
components such as glutathione (GSH) can coordinate and 
deactivate transition metal catalysts. In recent years, numerous 
transition metal mediated reactions have been shown to function 
under biological conditions, albeit with low productivity rarely 
exceeding a few turnovers.70,71  
Lin and coworkers used Pd-catalyzed Suzuki coupling to label 
proteins on mammalian cell surfaces (Figure 6b).72 Bradley and 
coworkers carried out Pd-catalyzed Suzuki coupling inside 
cells.73 Meggers and coworkers demonstrated the alkylating 
activity of a Ru piano stool complex in vivo (Figure 6b).74 Sadler 
and coworkers used various transition metal piano stool 
complexes in human cancer cell lines as catalysts to shift the 
equilibrium between NADP+ and NADPH towards NADPH which 
triggered cell death. The IC50 of the transition metal complex of < 
5 µM in the presence of 2 mM sodium formate were 
determined.75 These are encouraging reports with respect to 
applications of AMEs in vivo.  
Ward and coworker observed that artificial transfer 
hydrogenases based on Noyori-type biotinylated iridium piano 
stool catalysts are inactive in E. coli lysates which hampers the 
establishment of high-throughput genetic screening assays.76 
They recently demonstrated that, upon diamide-triggered 
oxidation of glutathione, the AMEs remain functional in cell free 
extracts and even in cell lysates, Figure 6b. 
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7. Enzyme Models 
The oxygen transporter sperm whale myoglobin is a small heme 
protein. It can be readily expressed in E. coli and has been used 
as an engineering platform for novel catalytic activities such as 
sulfoxidation77 and hydroxylation.78 In an seminal study, Lu and 
coworkers demonstrated that introduction of a His facial triad 
and a Glu into myglobin in the close proximity to the heme 
moiety allows binding of a second iron and leads to emergent 
nitric oxide reductase activity.79,80 The structurally characterized 
model confirmed the successful design. Heme-copper oxidases 
are heme proteins that contain a Cu center in the proximity to 
the iron heme center. An additional feature of the heme-copper 
oxidase active site is an unusual, conserved covalent link 
between a neighboring Tyr-C and an His-N. The specific role 
of this Tyr-His dimer in dioxygen reduction is unresolved. Wang, 
Lu and coworkers set out to investigate this functionality by 
introducing the UAA Tyr-C-imidazole in position F33 of CuBMb, 
a myoglobin construct with an additional engineered copper 
binding site. This protein displays significant active-site similarity 
with heme-copper oxidase.81 Upon addition of CuII to this mutant, 
the rate of water production increased 4-fold vs. a control that 
contained the CuII but only Tyr in position 33. Surprisingly, the 
absence of CuII did not significantly diminish oxidase activity. 
However, the frequency of production of reactive oxygen 
species (superoxide and peroxide) as side products decreased 
significantly upon addition of CuII. A TON of >1000 was 
observed for this enzyme. In a related study, Lu and coworkers 
examined whether positioning the active Tyr residue in another 
position than F33 relative to the CuB side in myoglobin CuBMb 
could improve oxidase activity. Mutant G65Y-CuBMb turned out 
to be a much better oxidase than F33Y-CuBMb producing at 
least 1000 turnovers.82 
In the next study, the group investigated if the oxidase activity of 
CuBMb-F33Y can be further improved by systematic tuning of 
the Fe-Cu redox potential.83 While natural heme-copper 
oxidases have redox potentials varying between -59 and +365 
mV that of model CuBMb-F33Y is +95 mV. It was speculated that 
increasing this value would correlate with an improved O2 
reduction activity. To test this hypothesis, residue S92 which 
forms an H-bond with axial His93 was chosen for mutagenesis 
into Ala: increased hydrophobicity at this position was expected 
to increase the redox potential. Gratifyingly, mutant CuBMb-
S92A-F33Y has a redox potential of +123 mV. Next, the heme 
prosthetic group was targeted for derivatization to increase the 
redox potential. Heme a carries an extended sesquiterpene 
substituent  and has been reported to have an increased redox 
potential vs. heme b, the cofactor in heme-copper oxidase, that 
contains a vinyl group in the same position. Since 
supplementation of CuBMb-F33Y with heme a yielded insoluble 
protein, heme derivatives with the alternative electron-
withdrawing substituents acetyl and formyl were prepared and 
incubated with CuBMb-F33Y. The resulting diformyl-substituted 
heme b inside CuBMb-F33Y yielded an AME with a redox 
potential of +320 mV, almost as high as that of bovine heart 
heme-copper oxidase (+365 mV). The increased redox potential 
correlates with an O2 reduction rate enhancement of nearly 10-
fold vs. heme b loaded CuBMb-F33Y. The reaction mechanism 
of heme-copper oxidase dioxygen reduction is believed to 
involve an intermediate tyrosyl radical at the Tyr-His residue in  
Figure 7. Crystal structure of heme-copper oxidase model CuBMb_F33Y.  
 
 
 
the active site. Using model CuBMb-F33Y Lu and coworkers 
demonstrated by EPR measurements that a Tyr radical can 
indeed be observed as a short-lived reaction intermediate.84  
 
8. Conclusion and Outlook 
Today, chemistry is striving for “greener” reaction processes 
which are more economical, energy-saving and environmentally 
benign. At the same time there is a need for the light-driven 
production of high-energy compounds as renewable energy 
sources from cheap and abundant starting materials. As implied 
in this microreview, AMEs that combine biomolecular with 
chemical diversity might offer solutions to these pressing 
demands. Initially, AMEs were designed as isolated entities to 
modify the selectivity and activity of catalytically active metal 
species.85,86 While the optimization of AMEs by genetic and 
chemical means is far from accomplished, one aims now at 
employing AMEs in cascade reactions in concert with chemo- 
and biocatalysts and ultimately in synthetic biological systems.87 
The protein scaffold offers a particular protective 
microenvironment for functional metal centers and AMEs are 
accordingly promising candidates for interfacing synthetic 
chemical with biological processes.88 The strategy of natural 
metalloenzyme repurposing benefits from its genuine in vivo 
compatibility but is likely limited in the accessible reaction 
repertoire.89 In contrast, the approach of embedding artificial 
metallocofactors into protein scaffolds holds the promise to 
enable a wide variety of catalytic abiological reaction types in 
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vivo. However, present hybrid catalysts and in particular their 
artificial prosthetic groups are often characterized by a limited in 
vivo compatibility. Tezcan and coworkers have demonstrated 
that a catalytic ZnII cofactor can generate an artificial hydrolase 
in the E. coli periplasm.7 While this is higly encouraging, it will be 
crucial to develop strategies that allow even larger multiatomic 
metallocofactors to assemble with their protein partners in 
cellulo to form functional AMEs. Ultimately, the creation of 
machinery for artificial metallocofactor biosynthesis and 
assembly with the scaffold protein would be desirable.  
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